Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 192   

Articles published

PFE 33.87 +0.55 (1.65%)
price chart
You Can't Ignore This News on Pfizer Inc. (PFE) Stock
Pfizer Inc. (NYSE:PFE) has finally decided what investors wanted to hear. The world's second-largest pharmaceutical company has given up the idea to split its business, ending years of uncertainty and speculations which had surrounded PFE stock.
Filing Analysis: Blackrock Institutional Trust Company Has Trimmed Holding ...  Chester News
Pfizer Inc. (NYSE:PFE) Prevnar 13, Losing Sales Momentum?
Furthermore, the company's vaccine portfolio has seen a consistent sequential growth in sales in 2015. For the full-year, the portfolio had recorded a 44% sales increase.
Pfizer: No Split, No Problem?  Seeking Alpha
Significant Ownership Change: Santa Barbara Asset Management LLC Boosted ...  Chester News
Brokerages Set Pfizer Inc. (NYSE:PFE) Target Price at $38.80
Pfizer logo Shares of Pfizer Inc. (NYSE:PFE) have earned an average recommendation of “Buy” from the twenty-six ratings firms that are covering the stock.
Pfizer, Inc. (NYSE:PFE) Mean Price Target At $39.40  Equities Focus
Ownership Change: Pfizer INC (PFE) Market Value Rose While Green Owl Capital ...
Green Owl Capital Management Llc decreased its stake in Pfizer Inc (PFE) by 97.52% based on its latest 2016Q2 regulatory filing with the SEC.
Pfizer Inc. (NYSE:PFE) Acquisition Of Medivation, Inc. (NASDAQ:MDVN) To Close ...
The waiting period relating to the Pfizer Inc. (NYSE:PFE) pending acquisition of Medivation, Inc. (NASDAQ:MDVN) has already expired last week as per the amended Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Pfizer (PFE) Closes Medivation (MDVN) Acquisition
Stocks to Track: Great Plains Energy Incorporated (NYSE:GXP), Pfizer Inc ...  NYSE Journal (press release)
Analysts: Pfizer Inc. (NYSE:PFE) stock is worth $39.47
Pfizer Inc. (NYSE:PFE) down -2.43% for the past 5 days, is under coverage of 21 analysts who collectively assign a hold rating on stock.
Pfizer Inc. (NYSE:PFE) Analyst Opinion  The Independent Republic
Pfizer decides against split-up; more deals seen likely
NEW YORK Pfizer Inc (PFE.N), which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines.
Pfizer Throws Out Plan to Split Into Two Companies  Wall Street Journal
Pfizer Shares Retreat After Company Decides Against Break-Up  ETF Daily News (blog)
OncoImmune Announces Option and License Agreement with Pfizer Inc.
ROCKVILLE, Md.--(BUSINESS WIRE)--OncoImmune, Inc. today announced that it has entered into an exclusive option and license agreement with Pfizer Inc. (NYSE: PFE) for ONC-392, a novel, differentiated preclinical anti-CTLA4 monoclonal antibody in a ...
Pfizer Seals License Deal with OncoImmune For Monoclonal Antibody ONC-392 In ...  Post News
Better Buy: Pfizer Inc. vs. AbbVie Inc.
If it sounds like Pfizer is trying to buy its way to growth, it's because that's exactly what the company is attempting to do.
What Pfizer Inc. (NYSE:PFE) Licensing Deal With OncoImmune, Inc. Means For ...
With its latest option and licensing agreement, Pfizer is seeking to evaluate ONC-392 and other potential anti-CTLA4 monoclonal antibodies from OncoImmune.
Pfizer Inc. (NYSE:PFE) Earns Consensus Hold Rating  Review Fortune
Pfizer Inc. (PFE): Fitch Affirms Ratings Over Decision To Scrap The Split  TCC